High-sensitivity troponin predicts coronary disease outcomes in type 2 diabetes but yields no benefit in selecting patients for revascularisation

Commentary on: Everett BM, Brooks MM, Vlachos HE, et al.., BARI 2D Study Group. Troponin and cardiac events in stable ischemic heart disease and diabetes. N Engl J Med 2015;373:610–20. Context High-sensitivity troponin (hs-TnT) assays have been developed for early recognition of patients with acute coronary syndrome (ACS). Additionally, hs-TnT has been shown to be a feasible tool for assessing risk among patients with heart failure. Even though efforts have been made to improve prognosis among patients with coronary artery disease (CAD) with high-risk features, most adverse events occur in patients without these features. Therefore, novel risk markers for ‘intermediate risk’ participants are needed. Recent evidence presents hs-TnT as a promising marker for adverse events among patients with stable CAD.1 2 The pathophysiological background for these findings and therapeutic options related to elevated hs-TnT levels are unknown. Methods The study in...
Source: Evidence-Based Medicine - Category: Internal Medicine Authors: Tags: Clinical trials (epidemiology), Drugs: cardiovascular system, Stroke, Interventional cardiology, Ischaemic heart disease, Radiology, Clinical diagnostic tests, Diabetes Therapeutics/Prevention Source Type: research